产品详情
查看大图

  • 产品名称：EPHReceptorB4(EPHB4)(AA17-539)(Active)protein(Histag)

  • 产品型号：
  • 产品厂商：ACROBiosystems
  • 产品文档：
你添加了1件商品 查看购物车
简单介绍：
EPHReceptorB4(EPHB4)(AA17-539)(Active)protein(Histag)
详情介绍：
Characteristics This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 57.8 kDa. The protein migrates as 65-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity >97 % as determined by SDS-PAGE.
Sterility 0.22 μm filtered
Endotoxin Level Less than 1.0 EU per μg by the LAL method.
ProductDetails: Biological Activity Comment Biological Activity: Measured by its binding ability in a functional ELISA. Immobilized rhEPHB4 at 2 μg/mL ( 100 μL/well ) can bind human EphrinB2 with a linear range of 0.8 - 85 ng/mL.
Background Ephrin type-B receptor 4(EPHB4) is also known as HTK, MYK1 and TYRO11,is a member of Eph family. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. The protein encoded by EPHB4 binds to Ephrin-B2 and plays an essential role in vascular development. EPHB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EPHB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis and tumor growth. Incontrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EPHB4 is associated with prostate cancer and highly malignant breast cancers, accordingly, EPHB4 has potential application as a therapeutic candidate.
Molecular Weight 57.8 kDa
NCBI Accession NP_004435
UniProt P54760
Pathways RTK Signaling
Restrictions For Research Use only
Format Lyophilized
Reconstitution Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Buffer PBS, pH 7.4
Handling Advice Avoid repeated freeze-thaw cycles.
Storage -20 °C
Storage Comment No activity loss was observed after storage at: 4-8°C for 1 year in lyophilized state 4-8°C for 1 month under sterile conditions after reconstitution -20°C to -70°C for 3 months under sterile conditions after reconstitution
Supplier Images
SDS-PAGE (SDS) image for EPH Receptor B4 (EPHB4) (AA 17-539) (Active) protein (His tag) (ABIN2181023) Human EphB4, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained ov...
Background publications Kertesz, Krasnoperov, Reddy, Leshanski, Kumar, Zozulya, Gill: "The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth." in: Blood, Vol. 107, Issue 6, pp. 2330-8, 2006 (PubMed).

Noren, Foos, Hauser, Pasquale: "The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway." in: Nature cell biology, Vol. 8, Issue 8, pp. 815-25, 2006 (PubMed).

Xia, Kumar, Masood, Zhu, Reddy, Krasnoperov, Quinn, Henshall, Sutherland, Pinski, Daneshmand, Buscarini, Stein, Zhong, Broek, Roy-Burman, Gill: "EphB4 expression and biological significance in prostate cancer." in: Cancer research, Vol. 65, Issue 11, pp. 4623-32, 2005 (PubMed).

Bennett, Wang, Kuang, Wang, Groopman, Goeddel, Scadden: "Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily." in: The Journal of biological chemistry, Vol. 269, Issue 19, pp. 14211-8, 1994 (PubMed).